In Vitro Fertilization Ivf MarketSize, Share & Industry Analysis, 2026-2034By TypeBy DevicesBy ReagentsBy End-userBy Age Group
Full title & scope — all 5 axes with their segments
In Vitro Fertilization Ivf Market Size, Share & Industry Analysis, By Type (Intrauterine Insemination, Intracytoplasmic Sperm Injection, IVF Using Donor Eggs), By Devices (Imaging Systems, Sperm Separation System, Ovum Aspiration Pump, Micromanipulator, Cryosystem), By Reagents (Embryo Culture Media, Cryopreservation Media, Sperm Processing Media, Ovum Processing Media), By End-user (Fertility Clinics, Hospitals, Clinical Research Centers), By Age Group (Under 35 Years, 35 to 40 Years, Above 40 Years), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By TypeIntrauterine Insemination · Intracytoplasmic Sperm Injection · IVF Using Donor Eggs
- 02By DevicesImaging Systems · Sperm Separation System · Ovum Aspiration Pump
- 03By ReagentsEmbryo Culture Media · Cryopreservation Media · Sperm Processing Media
- 04By End-userFertility Clinics · Hospitals · Clinical Research Centers
- 05By Age GroupUnder 35 Years · 35 to 40 Years · Above 40 Years
- 06By Region
Market Analysis & Outlook
In vitro fertilization is an assisted reproductive procedure in which eggs are retrieved from the ovaries and fertilized with sperm outside the body, with the resulting embryo transferred to the uterus; the category covers the instruments, culture media and cryopreservation systems used at each stage of the procedure alongside intrauterine insemination and donor-egg variants performed under the same clinical protocol. Buyers are fertility clinics, hospital reproductive medicine units and clinical research centers that purchase imaging, aspiration, micromanipulation and cryostorage equipment together with the consumable media each cycle requires.
The global in vitro fertilization ivf market stood at USD 30 billion in 2025. A forecast-period rate of 6.99% takes it to USD 55.14 billion by 2034, and the study reports every year in between, passing USD 20.91 billion in 2020, USD 27.92 billion in 2024, USD 32.1 billion in 2026 and USD 42.07 billion in 2030.
The type mix shifts over the period. Intracytoplasmic Sperm Injection is the largest line in 2025 at USD 16.5 billion, a 55% share, moving to USD 28.67 billion and 52% by 2034. IVF Using Donor Eggs grows fastest at 10.99%, taking its share from 15% to 21%, while Intrauterine Insemination grows slowest at 5.75%. The lines gaining share are IVF Using Donor Eggs. Intrauterine Insemination and Intracytoplasmic Sperm Injection lose share without losing revenue.
The devices split puts Imaging Systems first, at USD 9 billion and 30% of revenue in 2025, rising to USD 14.89 billion and 27% in 2034. Cryosystem grows faster at 11.64% against 5.76%, moving from 15% of revenue to 21.98% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.
North America is the largest region at 32% of 2025 revenue, worth USD 9.6 billion and reaching USD 15.99 billion by 2034. Asia Pacific follows at 30%, moving from USD 9 billion to USD 18.75 billion, and Middle East and Africa is the smallest at 6%. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.
Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 30 billion in 2025 to USD 55.14 billion in 2034, a compound annual rate of 6.99%, having reached USD 27.92 billion in 2024 from USD 20.91 billion in 2020.
- The largest line by type is Intracytoplasmic Sperm Injection, worth USD 16.5 billion and 55% of revenue in 2025, rising to USD 28.67 billion and 52% by 2034.
- Fastest growth on the type axis belongs to IVF Using Donor Eggs: 10.99% a year, USD 4.5 billion to USD 11.58 billion, and a share moving from 15% to 21%.
- Against a base case of USD 55.14 billion in 2034, the study also reports a bear case at USD 44.58 billion and a bull case at USD 66.78 billion, with the assumptions behind each set out separately.
- 32% of 2025 revenue is generated in North America, worth USD 9.6 billion and rising to USD 15.99 billion by 2034; Middle East and Africa is smallest at 6%.
- 81.98% of North America's base-year revenue comes from the United States alone: USD 7.87 billion in 2025, rising to USD 12.79 billion by 2034, which is why it is that region's worked example.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By By Type
Base year 2025Intracytoplasmic Sperm Injection leads with 55.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 6.99% compounding underneath both.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
IVF Using Donor Eggs outpaces Intrauterine Insemination. IVF Using Donor Eggs grows at 10.99% across 2026-2034 against 5.75% for Intrauterine Insemination, the widest spread on the type axis. By 2034 the two sit at 21% and 27.01% of revenue, against 15% and 30% in 2025. Revenue rises on both sides; USD 4.5 billion to USD 11.58 billion and USD 9 billion to USD 14.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Asia Pacific and Latin America gain regional share. Asia Pacific moves from 30% of revenue in 2025 to 34.01% in 2034, worth USD 9 billion rising to USD 18.75 billion; Latin America moves from 6% of revenue in 2025 to 7% in 2034, worth USD 1.8 billion rising to USD 3.86 billion. Share moves off the others in turn: North America at 32% moving to 29%, Europe at 26% moving to 24%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 6.99% without a step change. Fifteen years of revenue run USD 20.91 billion in 2020, USD 27.92 billion in 2024, USD 30 billion in 2025, USD 32.1 billion in 2026, USD 42.07 billion in 2030 and USD 55.14 billion in 2034. Against 7.49% through the historical period, the 6.99% forecast rate is a continuation; no year in the series interrupts it. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
10.99% growth in IVF Using Donor Eggs, against 6.99% for the market as a whole, moves it from USD 4.5 billion and 15% of revenue in 2025 to USD 11.58 billion and 21% in 2034. The market's overall 6.99% depends on that rate holding: at the 5.75% recorded by Intrauterine Insemination, the same revenue base would compound to a materially smaller 2034 total. Exposure to this line, not to the market as a whole, is what determines a supplier's own rate.
- 02Growth lands where the revenue already is
North America is the largest region at USD 9.6 billion in 2025, 32% of global revenue, and reaches USD 15.99 billion by 2034 while holding 29%. Asia Pacific is next at 30% of revenue, USD 9 billion in 2025 and USD 18.75 billion in 2034. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03The trend is already in the record
Revenue rose through USD 20.91 billion in 2020, USD 27.92 billion in 2024 and USD 30 billion in 2025, a compound 7.49% across the historical period. The forecast period then runs at 6.99%, ending 2034 at USD 55.14 billion. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 6.99% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising infertility prevalence tied to delayed childbearing | High | +8.5 | High | High | High |
| 2 | Expansion of insurance and employer fertility-benefit mandates | High | +6.2 | High | Medium | Medium |
| 3 | Adoption of advanced IVF add-on procedures and vitrification | Medium-High | +4.8 | Medium | High | High |
| 4 | Expansion of fertility clinic networks and cross-border care in Asia Pacific | Medium-High | +4.1 | Medium | Medium | High |
| 5 | Broader family formation among single-parent and same-sex prospective parents | Medium | +2.6 | Low | Medium | Medium |
| 6 | Others | Low | +4.14 | Low | Low | Low |
| Total | +30.34 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High out-of-pocket treatment cost limiting access in price-sensitive markets | Medium-High | −2.7 | High | Medium | Medium |
| 2 | Regulatory and ethical restrictions on donor-gamete and embryo procedures in select countries | Medium | −1.6 | Medium | Medium | Low |
| 3 | Treatment discontinuation from the physical and psychological burden of repeated cycles | Medium | −0.9 | Medium | Medium | Medium |
| Total | −5.2 | |||||
Drivers contribute 30.34 Billion and restraints remove 5.2 Billion, a net 25.14 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 6.99% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Where the forecast could miss: slower rollout of insurance mandates and continued high out-of-pocket cost in price-sensitive markets keep cycle volume growth below the base case, particularly across Latin America and parts of Asia Pacific. That path reaches USD 44.58 billion by 2034 instead of USD 55.14 billion, off an unchanged USD 30 billion in 2025.
- 02The largest line is not the fastest
With 55% of 2025 revenue (USD 16.5 billion) Intracytoplasmic Sperm Injection is where most of the market sits, and it grows at only 6.33% against the market's 6.99%. Revenue still reaches USD 28.67 billion by 2034 and share still falls to 52%: a drag on the average, not a decline.
Market Opportunities
Upside case: USD 66.78 billion by 2034
Market Opportunities
2- 01Upside case: USD 66.78 billion by 2034
What would beat the forecast: faster expansion of insurance and employer fertility-benefit mandates, combined with quicker adoption of frozen embryo transfer as the default protocol, pulls cycle volume growth above the base case. That case reaches USD 66.78 billion in 2034 against USD 55.14 billion, and it is worth testing against a reader's own read of the market.
- 02The opening is on the type axis, not the regional one
Share on the type axis moves toward IVF Using Donor Eggs, from 15% in 2025 to 21% in 2034, on 10.99% growth against the market's 6.99% and revenue rising from USD 4.5 billion to USD 11.58 billion. Taking position there does not require displacing whoever holds Intracytoplasmic Sperm Injection, which is the harder and more expensive fight.
Market Challenges
One type line carries the market
Market Challenges
2- 01One type line carries the market
USD 16.5 billion of 2025 revenue sits in Intracytoplasmic Sperm Injection, 55% of the total, and it is still 52% at USD 28.67 billion nine years later. That concentration means the market's own forecast is, to a large extent, a forecast for one type line.
- 02North America is largely the United States
Of North America's USD 9.6 billion in 2025, USD 7.87 billion (81.98%) comes from the United States alone, rising to USD 12.79 billion by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesfive segmentation axes are reported; by type, by devices, reagents, end-user and age group. They are alternative readings of one revenue pool, not parts that sum to it.
All three type lines expand in revenue terms over the forecast period. Share is the dividing line; one takes it, the others cede it.
By Type · 3 segments
Intracytoplasmic Sperm Injection Held the Dominant Share of the Type Segment in 2025
- Largest Intracytoplasmic Sperm Injection · 55%
- Fastest IVF Using Donor Eggs · 11%
- Moves most IVF Using Donor Eggs · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Intrauterine Insemination | $9B | 30% | $14.89B | 27%-3 | 5.8% |
| Intracytoplasmic Sperm Injection | $16.50B | 55% | $28.67B | 52%-3 | 6.3% |
| IVF Using Donor Eggs | $4.50B | 15% | $11.58B | 21%+6 | 11% |
ICSI leads because it is the default fertilization method whenever male-factor infertility is present, a condition found in a majority of cycles today; intrauterine insemination adds a second, lower-intensity procedure under this same axis. Donor-egg IVF grows fastest as more patients begin treatment at an older reproductive age, and improved vitrified donor-egg logistics make cross-clinic and cross-border sourcing more workable than it once was. The order does not change: Intracytoplasmic Sperm Injection is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Devices · 5 segments
Scale in Imaging Systems and Growth in Cryosystem Define the Devices Axis
- Largest Imaging Systems · 30%
- Fastest Cryosystem · 11.6%
- Moves most Cryosystem · +7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Imaging Systems | $9B | 30% | $14.89B | 27%-3 | 5.8% |
| Sperm Separation System | $3.60B | 12% | $6.07B | 11%-1 | 6% |
| Ovum Aspiration Pump | $6B | 20% | $9.93B | 18%-2 | 5.8% |
| Micromanipulator | $6.90B | 23% | $12.13B | 22%-1 | 6.5% |
| Cryosystem | $4.50B | 15% | $12.12B | 22%+7 | 11.6% |
Imaging systems lead because ultrasound-guided monitoring is used in every treatment cycle regardless of protocol, giving this category the broadest installed base across clinics of every size. Cryosystems grow fastest as vitrification replaces slow-freeze methods and frozen embryo transfer increasingly replaces fresh transfer as the default protocol, raising the cryostorage equipment a typical clinic needs per patient. By 2034 Imaging Systems is still ahead, making this a shift in weight, not a change of leader.
By Reagents · 4 segments
Cryopreservation Media Outpaces the Axis While Embryo Culture Media Holds the Largest Share
- Largest Embryo Culture Media · 45%
- Fastest Cryopreservation Media · 8.8%
- Moves most Cryopreservation Media · +4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Embryo Culture Media | $13.50B | 45% | $23.16B | 42%-3 | 6.2% |
| Cryopreservation Media | $7.50B | 25% | $15.99B | 29%+4 | 8.8% |
| Sperm Processing Media | $4.50B | 15% | $7.72B | 14%-1 | 6.2% |
| Ovum Processing Media | $4.50B | 15% | $8.27B | 15% | 7% |
Embryo culture media leads because it is consumed at a fixed volume in every single cycle regardless of which protocol or patient age group is involved, making it the largest recurring purchase line for any clinic. Cryopreservation media grows fastest as clinics increasingly freeze all embryos for a later transfer instead of proceeding with a fresh transfer in the same cycle. By 2034 Embryo Culture Media is still ahead, making this a shift in weight, not a change of leader.
By End-user · 3 segments
Fertility Clinics Holds the Largest End-user Share and Is Still the Quickest to Grow
- Largest Fertility Clinics · 68%
- Fastest Fertility Clinics · 7.3%
- Moves most Fertility Clinics · +2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Fertility Clinics | $20.40B | 68% | $38.60B | 70%+2 | 7.3% |
| Hospitals | $8.10B | 27% | $13.78B | 25%-2 | 6.1% |
| Clinical Research Centers | $1.50B | 5% | $2.76B | 5% | 7% |
Fertility clinics lead because dedicated specialty centers concentrate the equipment, trained staff and patient volume that hospital-based programs rarely match at the same scale. Clinics also grow fastest as chain operators open new locations and absorb procedure volume from smaller hospital programs that are scaling back or closing their reproductive medicine units. The order does not change: Fertility Clinics is still largest in 2034, and what moves is how much it holds.
By Age Group · 3 segments
Under 35 Years Held the Dominant Share of the Age group Segment in 2025
- Largest Under 35 Years · 40%
- Fastest Above 40 Years · 9.5%
- Moves most Under 35 Years · -5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Under 35 Years | $12B | 40% | $19.30B | 35%-5 | 5.4% |
| 35 to 40 Years | $11.40B | 38% | $20.95B | 38% | 7% |
| Above 40 Years | $6.60B | 22% | $14.89B | 27%+5 | 9.5% |
Patients under thirty five make up the largest share because natural conception still resolves many cases before treatment is sought at that age, keeping this group large on volume alone. The above-forty cohort grows fastest as more prospective parents delay childbearing into their late thirties and forties, an age at which declining egg quality makes assisted treatment necessary more often. By 2034 the largest line is 35 to 40 Years and no longer Under 35 Years, the one axis here where the order actually changes.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 32%
- By 2034 29%
- Revenue $9.60B → $15.99B
In North America, 32% of global revenue puts 2025 at USD 9.6 billion on the way to USD 15.99 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 29%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Intracytoplasmic Sperm Injection leads here as it does globally, at 55% of 2025 revenue, and IVF Using Donor Eggs again grows fastest at 10.99%. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 82% of it, growing 1.6×.
- In region 1 of 2
- Of region 82%
- Of global 26.2%
- Revenue $7.87B → $12.79B
81.98% of North America's base-year revenue comes from the United States; USD 7.87 billion, rising to USD 12.79 billion by 2034. 81.98% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Against regional totals of USD 9.6 billion in 2025 and USD 15.99 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Intracytoplasmic Sperm Injection at 55% of 2025 revenue, easing to 52% by 2034, and the fastest is IVF Using Donor Eggs at 10.99%, from 15% to 21%. Its 81.98% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.
In the United States, IVF-related devices, culture media, and embryology instruments are regulated by the Food and Drug Administration under its medical device framework, with classification determining whether a supplier needs premarket notification or premarket approval before marketing a product. Manufacturers must also comply with the FDA's quality system regulation covering design controls, labelling, and traceability. Fertility clinics and embryology laboratories operate under the Clinical Laboratory Improvement Amendments, which set personnel, proficiency testing, and quality standards for the laboratory side of treatment. Success-rate reporting to the Centers for Disease Control adds a public accountability layer that sits alongside device approval, though it does not substitute for it.
The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Intracytoplasmic Sperm Injection at 55% of 2025 revenue, and taking IVF Using Donor Eggs while it grows at 10.99%. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 15%
- Of global 4.8%
- Revenue $1.44B → $2.40B
Canada is sized at USD 1.44 billion in 2025, rising to USD 2.4 billion by 2034; 4.8% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 3rd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 3 of 5
- 2025 share 26%
- By 2034 24%
- Revenue $7.80B → $13.23B
In Europe, 26% of global revenue puts 2025 at USD 7.8 billion rising to USD 13.23 billion in 2034. Among the five regions it ranks third by revenue in both years.
Share settles at 24% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
The type mix reported at global level applies here, with Intracytoplasmic Sperm Injection the largest line at 55% of 2025 revenue and IVF Using Donor Eggs the fastest-growing at 10.99%. The full report breaks Europe out along every axis and by country.
Germany
The largest market in Europe, growing 1.6×.
- In region 1 of 2
- Of region 40%
- Of global 10.4%
- Revenue $3.12B → $5.03B
USD 3.12 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 5.03 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 7.8 billion in 2025 and USD 13.23 billion in 2034, it is the country the full report breaks out in detail.
Germany buys along the same lines as the market globally; Intracytoplasmic Sperm Injection first at 55% of 2025 revenue and 52% in 2034, IVF Using Donor Eggs fastest at 10.99% on a share moving from 15% to 21%. Because the country carries 40% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Germany by type separately.
In Germany, medical devices used in IVF, including catheters, culture media, and cryopreservation equipment, fall under the EU Medical Device Regulation and require CE marking following a conformity assessment appropriate to their risk class. The national competent authority, BfArM, oversees market surveillance, while notified bodies certify higher-risk devices against harmonised standards covering quality management systems. Clinical practice itself is bounded by the Embryo Protection Act, a national law that restricts how embryos may be created, stored, and used, shaping what a supplier's product can be marketed to do inside a German laboratory. Labelling must reflect both the device's intended purpose and its conformity status.
The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in Germany across the type lines above. The commercially relevant division is 55% of 2025 revenue in Intracytoplasmic Sperm Injection, where the volume is, against 10.99% growth in IVF Using Donor Eggs, where share moves. That makes Europe a 26% share of 2025 global revenue, USD 7.8 billion rising to USD 13.23 billion, for any supplier deciding where to concentrate.
United Kingdom
2nd-largest in Europe, growing 1.6×.
- In region 2 of 2
- Of region 25%
- Of global 6.5%
- Revenue $1.95B → $3.18B
Within Europe, the United Kingdom accounts for 25% of regional revenue and 6.5% of the global total, worth USD 1.95 billion in 2025 and USD 3.18 billion by 2034.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 4 points of share by 2034, while revenue still grows 2.1×.
- Rank 2 of 5
- 2025 share 30%
- By 2034 34%
- Revenue $9B → $18.75B
30% of the global in vitro fertilization ivf market sits in Asia Pacific in 2025, worth USD 9 billion on the way to USD 18.75 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Share climbs to 34.01% by 2034, at a pace above the 6.99% global rate, so this region warrants separate treatment and should not be scaled off the total.
The type mix reported at global level applies here, with Intracytoplasmic Sperm Injection the largest line at 55% of 2025 revenue and IVF Using Donor Eggs the fastest-growing at 10.99%. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.3×.
- In region 1 of 2
- Of region 40%
- Of global 12%
- Revenue $3.60B → $8.44B
USD 3.6 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 8.44 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Set against USD 9 billion and USD 18.75 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in China follows the type mix reported at global level: Intracytoplasmic Sperm Injection is the largest line at 55% of 2025 revenue, moving to 52% by 2034, while IVF Using Donor Eggs grows fastest at 10.99% and takes its share from 15% to 21%. Since 40% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for China appears on its own in the full report.
In China, medical devices, reagents, and culture media used in IVF are regulated by the National Medical Products Administration, which assigns products to a risk-based classification and requires registration before a supplier may sell into the market. Registration typically calls for clinical evaluation data, manufacturing quality certification, and Chinese-language labelling that matches the approved product description. Separately, the National Health Commission licenses assisted reproductive technology clinics and sets rules on how embryology laboratories must operate, so a device's registration status is only one part of what a supplier needs to bring a product into clinical use. Imported products face additional scrutiny of their manufacturing facilities before registration is granted.
Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands) are the suppliers covered in China. Two different problems sit on the same axis: holding Intracytoplasmic Sperm Injection at 55% of 2025 revenue, and taking IVF Using Donor Eggs while it grows at 10.99%. Weighting toward Asia Pacific means competing for 30% of 2025 global revenue, a base of USD 9 billion moving to USD 18.75 billion across the forecast period.
Japan
2nd-largest in Asia Pacific, growing 1.8×.
- In region 2 of 2
- Of region 35%
- Of global 10.5%
- Revenue $3.15B → $5.63B
Within Asia Pacific, Japan accounts for 35% of regional revenue and 10.5% of the global total, worth USD 3.15 billion in 2025 and USD 5.63 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 2.1×.
- Rank 4 of 5
- 2025 share 6%
- By 2034 7%
- Revenue $1.80B → $3.86B
6% of the global in vitro fertilization ivf market sits in Latin America in 2025, worth USD 1.8 billion rising to USD 3.86 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
Share climbs to 7% by 2034, because it outgrows the market's 6.99%; the revenue added here is disproportionate to where the region started.
Within the region the type split tracks the global one; 55% of 2025 revenue in Intracytoplasmic Sperm Injection, fastest growth of 10.99% in IVF Using Donor Eggs. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 2.1×.
- In region 1 of 2
- Of region 50%
- Of global 3%
- Revenue $0.90B → $1.93B
Brazil is the largest market within Latin America, generating USD 0.9 billion in 2025 and projected to reach USD 1.93 billion by 2034. At 50% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 1.8 billion to USD 3.86 billion over the same period, and this is the market carrying the country-level detail in the full report.
Brazil buys along the same lines as the market globally; Intracytoplasmic Sperm Injection first at 55% of 2025 revenue and 52% in 2034, IVF Using Donor Eggs fastest at 10.99% on a share moving from 15% to 21%. Because the country carries 50% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Brazil by type separately.
In Brazil, medical devices and reagents used in IVF procedures are regulated by ANVISA, the national health surveillance agency, which requires product registration based on risk classification along with evidence of conformity to applicable technical standards before a device can be marketed. Manufacturers must also demonstrate compliance with Good Manufacturing Practice requirements, verified through facility inspection for higher-risk categories. The Federal Council of Medicine issues separate resolutions governing how assisted reproduction is practised clinically, covering matters such as embryo handling and clinic accreditation, so a supplier's registration with ANVISA sits alongside professional rules that shape how its products are actually used in treatment.
Competition in Brazil runs between the suppliers this study tracks: Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands). The commercially relevant division is 55% of 2025 revenue in Intracytoplasmic Sperm Injection, where the volume is, against 10.99% growth in IVF Using Donor Eggs, where share moves. Weighting toward Latin America means competing for 6% of 2025 global revenue, a base of USD 1.8 billion moving to USD 3.86 billion across the forecast period.
Mexico
2nd-largest in Latin America, growing 2.1×.
- In region 2 of 2
- Of region 30%
- Of global 1.8%
- Revenue $0.54B → $1.16B
Mexico is sized at USD 0.54 billion in 2025, rising to USD 1.16 billion by 2034; 1.8% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 1.8×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $1.80B → $3.31B
6% of the global in vitro fertilization ivf market sits in Middle East and Africa in 2025, worth USD 1.8 billion with USD 3.31 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.
6% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Intracytoplasmic Sperm Injection largest at 55% of 2025 revenue, IVF Using Donor Eggs fastest at 10.99%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.8×.
- In region 1 of 2
- Of region 35%
- Of global 2.1%
- Revenue $0.63B → $1.16B
35% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.63 billion, rising to USD 1.16 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 1.8 billion and USD 3.31 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Intracytoplasmic Sperm Injection at 55% of 2025 revenue, easing to 52% by 2034, and the fastest is IVF Using Donor Eggs at 10.99%, from 15% to 21%. Its 35% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-type revenue for Saudi Arabia appears on its own in the full report.
In Saudi Arabia, medical devices and reagents used in IVF are regulated by the Saudi Food and Drug Authority, which requires a marketing authorisation before a product may be sold, based on a risk classification broadly aligned with international frameworks. Suppliers must show conformity to recognised technical standards and maintain labelling that matches the authorised product file. The Ministry of Health separately licenses fertility clinics and sets clinical rules for assisted reproduction, reflecting the country's own ethical and religious guidance on embryo handling, so device authorisation and clinical practice are governed through two distinct but connected channels.
The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in Saudi Arabia across the type lines above. Intracytoplasmic Sperm Injection, at 55% of 2025 revenue, is where the volume sits, and IVF Using Donor Eggs, growing at 10.99%, is where position changes hands over the forecast period. That makes Middle East and Africa a 6% share of 2025 global revenue, USD 1.8 billion rising to USD 3.31 billion, for any supplier deciding where to concentrate.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 1.8×.
- In region 2 of 2
- Of region 25%
- Of global 1.5%
- Revenue $0.45B → $0.83B
The United Arab Emirates is sized at USD 0.45 billion in 2025, rising to USD 0.83 billion by 2034; 1.5% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Devices, Reagents, End-User, Age Group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Intracytoplasmic Sperm Injection and Growth in IVF Using Donor Eggs Set the Terms of Competition
The study covers the following suppliers: Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands).
Where suppliers actually compete is along the type axis. 55% of 2025 revenue, worth USD 16.5 billion, is in Intracytoplasmic Sperm Injection, still 52% of the total in 2034; that is the position least likely to change hands. The line that changes hands is IVF Using Donor Eggs at 10.99%, well ahead of Intrauterine Insemination at 5.75%. Those are different problems, and a supplier strong in one is not thereby strong in the other; that is what sustains a field this size in a USD 30 billion market.
In IVF devices and reagents, scale in reagent and culture-media manufacturing matters most because clinics standardize on a single embryology media line across every cycle and rarely switch once outcomes are validated in-house. Regulatory clearance experience across the United States, European Union and Japan sets which suppliers can sell integrated equipment and media programs into the largest clinic networks, while distribution reach into hospital and government-funded programs decides access in the Gulf states and parts of Asia Pacific. The largest suppliers compete on breadth, offering imaging, aspiration, micromanipulation and cryostorage together with matched media; smaller and regional suppliers compete on price and close relationships with independent clinics.
Presence matters unevenly by region. With 32% of 2025 revenue in North America and 30% in Asia Pacific, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key In Vitro Fertilization Ivf Market Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Cooper Companies Inc. (US)
- Cook Group (US)
- Vitrolife (Sweden)
- Thermo Fisher ScientificInc. (US)
- Esco Micro Pte. Ltd. (Singapore)
- Genea Limited (Australia)
- IVFtech ApS (Denmark)
- FUJIFILM Irvine Scientific (US)
- The Baker CompanyInc. (US)
- Kitazato Corporation (Japan)
- Rocket Medical plc (UK)
- Hamilton Thorne Ltd. (US)
- ZEISS Group (Germany)
- FERTIPRO NV(Belgium)
- Gynotec B.V. (Netherlands)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Devices, Reagents, End-user, Age Group), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global In Vitro Fertilization Ivf Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global In Vitro Fertilization Ivf Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global In Vitro Fertilization Ivf Market Overview, By Devices, 2020–2034, Revenue (USD Billion)
Chapter 18.Global In Vitro Fertilization Ivf Market Overview, By Reagents, 2020–2034, Revenue (USD Billion)
Chapter 19.Global In Vitro Fertilization Ivf Market Overview, By End-user, 2020–2034, Revenue (USD Billion)
Chapter 20.Global In Vitro Fertilization Ivf Market Overview, By Age Group, 2020–2034, Revenue (USD Billion)
Chapter 21.Global In Vitro Fertilization Ivf Market Size — Segment Comparison
Chapter 22.Global In Vitro Fertilization Ivf Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America In Vitro Fertilization Ivf Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe In Vitro Fertilization Ivf Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific In Vitro Fertilization Ivf Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America In Vitro Fertilization Ivf Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa In Vitro Fertilization Ivf Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
3- 01Intrauterine Insemination
- 02Intracytoplasmic Sperm Injection
- 03IVF Using Donor Eggs
By Devices
5- 01Imaging Systems
- 02Sperm Separation System
- 03Ovum Aspiration Pump
- 04Micromanipulator
- 05Cryosystem
By Reagents
4- 01Embryo Culture Media
- 02Cryopreservation Media
- 03Sperm Processing Media
- 04Ovum Processing Media
By End-user
3- 01Fertility Clinics
- 02Hospitals
- 03Clinical Research Centers
By Age Group
3- 01Under 35 Years
- 0235 to 40 Years
- 03Above 40 Years
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
Market size was built upward from estimated annual IVF and IUI cycle volumes by country, cycle-specific realized pricing across embryology media, disposables and per-cycle equipment amortization, and reported average cycles performed per licensed fertility center. This bottom-up build was checked against disclosed revenue from the equipment and reagent suppliers named in this report, particularly the reagent and cryopreservation media lines that carry the highest attach rate per cycle. Where a country's implied cycle volume, drawn from national ART registries, produced a bottom-up figure that diverged from a supplier's disclosed regional revenue, the cycle-volume or price-per-cycle assumption was revisited and corrected rather than averaging the two figures together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target embryology lab directors and clinic procurement leads who select imaging, aspiration and cryopreservation equipment; reimbursement and benefits managers at insurers and employers who set fertility-benefit mandates; and regulatory affairs contacts at device and media manufacturers who track clearance timelines across the United States, European Union, Japan and China. Sampling is weighted toward North America, Western Europe and the higher-volume Asia Pacific markets, since clinic purchasing decisions and treatment protocols in these geographies set the pattern lower-volume markets tend to follow with a lag. Distribution and channel partners in the Gulf states and Latin America are included to capture how government-funded treatment programs shape local equipment procurement.
Desk research draws on published cycle and outcome statistics from national and regional ART registries, including the Society for Assisted Reproductive Technology's national summary reports, the European Society of Human Reproduction and Embryology's annual data collection, the UK Human Fertilisation and Embryology Authority register, and the International Committee for Monitoring Assisted Reproductive Technology's cross-country compilation. Device clearance filings from national regulators establish which imaging, aspiration and micromanipulation systems are approved for clinical use in each market, and customs classification records for embryology instruments and reagents corroborate the cross-border trade volumes implied by the bottom-up build.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected growth in annual treatment cycles, driven by rising infertility prevalence at later reproductive ages, the pace at which national and employer insurance mandates extend fertility benefit coverage, and the continuing shift from fresh to frozen embryo transfer that raises cryopreservation media and equipment intensity per patient. Pricing is assumed to hold flat in real terms in mature markets while easing gradually in higher-volume Asia Pacific markets as local manufacturing scales. The forecast normalizes for the temporary cycle backlog that built up during clinic closures earlier in the historical period, treating the subsequent catch-up demand as temporary and excluding it from the sustained growth rate assumed thereafter.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were checked by back-testing the bottom-up build against each country's recorded cycle-volume growth over the historical period and comparing the implied reagent and equipment revenue against supplier-disclosed regional sales for the same years. Segment share shifts, particularly the move toward donor-egg treatment and frozen embryo transfer, were reviewed against the same registry data used for sizing instead of being assumed to continue at a fixed rate. Sensitivities were tested on the price-per-cycle assumption and on the pace of insurance-mandate expansion in the United States and Western Europe, since both carry more forecast weight than any single country's cycle-volume estimate.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in the largest addressable segments, embryo culture media and the fertility-clinic channel, where cycle volumes are reported consistently across multiple national registries. It is thinner in donor-egg IVF and in several Middle Eastern and Latin American markets, where registry reporting is incomplete or delayed and government-funded program data is not always broken out separately from privately paid cycles. A structural risk to this estimate is a faster or slower pace of insurance-mandate expansion than assumed; either would move cycle volumes, and therefore reagent and equipment demand, without any change in the underlying prevalence of infertility.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the In Vitro Fertilization Ivf Market projected to reach?
USD 55.14 Billion by 2034, CAGR 6.99%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 32% of global revenue through 2034.
05Which segment leads the market?
Intracytoplasmic Sperm Injection is the largest line by Type, at 55% of revenue in 2025.
06Who are the key companies profiled?
Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium), Gynotec B.V. (Netherlands). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.